Nplate (romiplostim) for Injection, for Subcutaneous Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  April 2016 ADVERSE REACTIONS Clinical Trials Experience Bone Marrow Reticulin Formation and Collagen Fibrosis Nplate...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts